Evaluating VSJ-110 for treating dry eye
A Four-Week, Double-Masked, Randomized, Placebo-Controlled, Phase 2, Evaluation of the Safety and Efficacy of VSJ-110 Ophthalmic Solution in the Treatment of Dry Eye
PHASE2 · Vanda Pharmaceuticals · NCT06296966
This study is testing a new treatment called VSJ-110 to see if it can help adults with dry eye feel better compared to a placebo.
Quick facts
| Phase | PHASE2 |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Vanda Pharmaceuticals (industry) |
| Locations | 1 site (Andover, Massachusetts) |
| Trial ID | NCT06296966 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the safety and efficacy of a new treatment called VSJ-110 compared to a placebo for individuals suffering from dry eye. Participants will be monitored for their response to the treatment and any potential side effects. The study will involve adults aged 18 and older who meet specific eligibility criteria and are willing to attend all required visits. The findings could provide valuable insights into a new therapeutic option for managing dry eye symptoms.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older experiencing symptoms of dry eye.
Not a fit: Patients currently using disallowed medications or those who do not meet the eligibility criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could offer a new effective option for patients suffering from dry eye.
How similar studies have performed: While this specific approach is being evaluated in this trial, similar studies have shown promise in developing new treatments for dry eye.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Be at least 18 years of age of either gender and any race. * Provide written informed consent and sign the HIPAA form. * Be willing and able to follow all instructions and attend all study visits. Exclusion Criteria: * Use of any of the disallowed medications during the washout and study period.
Where this trial is running
Andover, Massachusetts
- Vanda Investigational Site — Andover, Massachusetts, United States (RECRUITING)
Study contacts
- Study coordinator: Vanda Pharmaceuticals Inc.
- Email: clinicaltrials@vandapharma.com
- Phone: 202-734-3400
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Dry Eye